212 related articles for article (PubMed ID: 38377196)
21. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.
Lee C; Jiang ZK; Planken S; Manzuk LK; Ortiz R; Hall M; Noorbehesht K; Ram S; Affolter T; Troche GE; Ihle NT; Johnson T; Ahn Y; Kraus M; Giddabasappa A
Mol Cancer Ther; 2023 Jul; 22(7):891-900. PubMed ID: 37186518
[TBL] [Abstract][Full Text] [Related]
23. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M; Novello S; Passiglia F
Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
[TBL] [Abstract][Full Text] [Related]
24. HER2 mediates clinical resistance to the KRAS
Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
[TBL] [Abstract][Full Text] [Related]
25. The KRAS
Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
[TBL] [Abstract][Full Text] [Related]
26. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.
Naim N; Moukheiber S; Daou S; Kourie HR
Crit Rev Oncol Hematol; 2021 Dec; 168():103524. PubMed ID: 34800654
[TBL] [Abstract][Full Text] [Related]
27. Targeting KRAS in Colorectal Cancer.
Wang C; Fakih M
Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
[TBL] [Abstract][Full Text] [Related]
28. DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS
Chiou LW; Chan CH; Jhuang YL; Yang CY; Jeng YM
J Biomed Sci; 2023 Jun; 30(1):50. PubMed ID: 37386628
[TBL] [Abstract][Full Text] [Related]
29. Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer.
Zhang Y; Liu L; Pei J; Ren Z; Deng Y; Yu K
Oncogene; 2024 Feb; 43(9):668-681. PubMed ID: 38191673
[TBL] [Abstract][Full Text] [Related]
30. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
Stites EC; Shaw AS
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
[TBL] [Abstract][Full Text] [Related]
31. Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model.
Kobayashi K; Terai H; Yasuda H; Hamamoto J; Hayashi Y; Takeuchi O; Mitsuishi Y; Masuzawa K; Manabe T; Ikemura S; Kawada I; Suzuki Y; Soejima K; Fukunaga K
Biochem Biophys Res Commun; 2021 Jan; 534():1-7. PubMed ID: 33302159
[TBL] [Abstract][Full Text] [Related]
32. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
33. KRAS
Lou K; Steri V; Ge AY; Hwang YC; Yogodzinski CH; Shkedi AR; Choi ALM; Mitchell DC; Swaney DL; Hann B; Gordan JD; Shokat KM; Gilbert LA
Sci Signal; 2019 May; 12(583):. PubMed ID: 31138768
[TBL] [Abstract][Full Text] [Related]
34. Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance.
Jiang Z; Li Y; Zhou X; Wen J; Zheng P; Zhu W
Bioorg Med Chem; 2024 Feb; 100():117627. PubMed ID: 38310752
[TBL] [Abstract][Full Text] [Related]
35. The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.
Saturno G; Lopes F; Niculescu-Duvaz I; Niculescu-Duvaz D; Zambon A; Davies L; Johnson L; Preece N; Lee R; Viros A; Holovanchuk D; Pedersen M; McLeary R; Lorigan P; Dhomen N; Fisher C; Banerji U; Dean E; Krebs MG; Gore M; Larkin J; Marais R; Springer C
Ann Oncol; 2021 Feb; 32(2):269-278. PubMed ID: 33130216
[TBL] [Abstract][Full Text] [Related]
36. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.
Veluswamy R; Mack PC; Houldsworth J; Elkhouly E; Hirsch FR
J Mol Diagn; 2021 May; 23(5):507-520. PubMed ID: 33618059
[TBL] [Abstract][Full Text] [Related]
37. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS
Ryan MB; Fece de la Cruz F; Phat S; Myers DT; Wong E; Shahzade HA; Hong CB; Corcoran RB
Clin Cancer Res; 2020 Apr; 26(7):1633-1643. PubMed ID: 31776128
[TBL] [Abstract][Full Text] [Related]
38. The promise and peril of KRAS G12C inhibitors.
Moore AR; Malek S
Cancer Cell; 2021 Aug; 39(8):1059-1061. PubMed ID: 34375610
[TBL] [Abstract][Full Text] [Related]
39. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
Lee A
Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
[TBL] [Abstract][Full Text] [Related]
40. Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.
Haider K; Sharma A; Yar MS; Yakkala PA; Shafi S; Kamal A
Expert Opin Drug Discov; 2022 Mar; 17(3):247-257. PubMed ID: 35084268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
